News · News & Updates
Stay up to date with Poseidon's latest progress, research breakthroughs, product approvals and corporate news
Our 4th-generation EGFR inhibitor NVP-201 met its primary endpoint in the pivotal Phase III trial...
Our innovative GLP-1/GIP/Glucagon triple agonist NVP-305 dosed the first patient in its Phase II obesity trial...
Our CD19-targeted CAR-T NVP-508 presented latest Phase II data at the 65th ASH Annual Meeting...